The role of Chloroquine phosphate on rheumatoid factor in patients with knee osteoarthritis
DOI:
https://doi.org/10.32007/jfacmedbaghdad1175Keywords:
Chloroquine phosphate, Knee osteoarthritis, , Rheumatoid factor, Immunoglobulin and DMARDAbstract
Background: Osteoarthritis (OA) is disorder of diarthrodial joints characterized clinically by pain and functional limitation. Rheumatoid factor (RF) represents one of routine laboratory tests that done for all patients have joint complaints. Chloroquine phosphate (CQP) is a disease modifying antirheumatic drug (DMARD) used for patients suffer from knee osteoarthritis (KOA) in order to reduce their RF value and improves the disease status.
Objective: To evaluate the effect of chloroquine phosphate on rheumatoid factor (RF) level in serum of patients with knee osteoarthritis KOA) Design: case report.
Subjects and methods: RF value were assessed quantitatively by ELISA technique before and after treatmtnt for a total of fifty five patients with KOA (30 femal and 25 male) their age ranged from (50-66 years) selected randomly from out patient clinic in Baghdad Teaching Hospital , Medical City Baghdad; suffering from KOA. All patients were treated with oral dosage form of CQP for one month twice daily.
Results: Mean serum RF level was significantly reduced (p<0.05) in serum of patients after treatment with CQP for one month.
Conclusion:CQP is a disease modifying antirheumatic drug (DMARD) used for patients suffering from KOA in order to reduce their RF value and improves the disease status.
Downloads
References
1.Hochberg MC :osteoarthritis ,B.Clinical features . In:Klippel JH ,Crofford LJ ,Weyand CM ,(eds).Atlanta , Georgia =Athritis foundation, 2001 ;p 289-293.
2.Schnitzer TJ :osteoarthritis (degenerative bone disease).In Bennett JC , Plum F (eds).Cecil Text book Of medicine.20th(ed)volume 2.W.B. Saunders company ,1998;p 1517-152'.
3.Ahmed MH , Osman MM (why does chloroquine impair renal function?.Medical hypotheses , 2007 ; 68 , 140-143.
https://doi.org/10.1016/j.mehy.2006.06.012 DOI: https://doi.org/10.1016/j.mehy.2006.06.012
4.Peter JB ,Shoenfeld y :Autoantibodies .Elsevier Sciences B.V. ,Amsterdam ,1996.
5.Witte T , Hartung K , Sachse C , Matthias T ,Fricke M , Khalden JR et al .Rheumatoid factors in systemic lupus erythrematous :Association with clinical and laboratory parameters .SLE study group.Rheumatol Int ,(2000);19,107-111.
https://doi.org/10.1007/s002960050112 DOI: https://doi.org/10.1007/s002960050112
6.Brandt KD :Osteoarthritis .In :Harrison's Principle of Internal Medicine 6th ed. Kasper DL (ed):McGraw Hill companies.(2005),p 2036-2045.
7.Kidd BL ,Photion A ,and Inglis JJ :The role of inflammatory mediators on nociception and pain in arthritis Novartis Found .Symp. 2004 ;260 :122-123. https://doi.org/10.1002/0470867639.ch9 DOI: https://doi.org/10.1002/0470867639.ch9
8.Jawad HH ,Salmans ,Mohammed L:The effect of chloroquine phosphate as disease modifying agent in osteoarthritis, a Ph D Thesis submitted to Baghdad College of Medicine and the committee of postgraduate studies in clinical pharmacology, 2004.
9.Petri M: Heydroxychloroquine use in the Baltimore Lupus cohort: Effects on lipid, glucose and thrombosis , Lupus, 1996; 5, 516
https://doi.org/10.1177/0961203396005001051 DOI: https://doi.org/10.1177/0961203396005001051
10.Karres I, Kremer JP, Dietl I, et al. (Choroquine inhibits proinflammatory cytokines release into human whole blood. Am J Physiology/ Regul Integ Comp Physiol, 1998; 274, 1058-1064. https://doi.org/10.1152/ajpregu.1998.274.4.R1058 DOI: https://doi.org/10.1152/ajpregu.1998.274.4.R1058
11.Fox RI, Kang HI: Mechanism of action of antimalarial drugs: inhibition of antigen processing and presentation. Lupus, 1993; 2, 59.
https://doi.org/10.1177/0961203393002001031 DOI: https://doi.org/10.1177/0961203393002001031
12.Fox RI: Antimalarial Drugs: Possible mechanisms of action in autoimmune disease and prospects for drug development. Lupus, 1996; 5, 54. https://doi.org/10.1177/0961203396005001031 DOI: https://doi.org/10.1177/0961203396005001031
13.Wallace DJ: Antimalarial therapies In: Dubois Lupus erythematosus, 5th ed, Wallace DJ, Hahn BH (eds), Williams Wilkins, Baltimore, 1997; P 117.
14.Stuhimeier KM: Mepacrine inhibit matrix metalloproteinases-1 (MMP-1) and MMP-9 activation in human fibroblast-like synoviocytes. J Rheumatol. 2003; 30, 2330. U/ml Baseline 1 month Pvalue T 22.1+2.18 10.29+0.8 S M 21.25+3.65 10.01+1.46 S F 22.65+2.79 10.47+0.93 S
Creative Commons Attribution 4.0 International license..
